CJC-1295 (no DAC), GHRP-2 10mg (Blend)

CJC-1295 (no DAC), GHRP-2 10mg (Blend) — research formula for studying GH axis regulation and receptor crosstalk in the anterior pituitary. Combines a short-acting GHRH analog with a ghrelin receptor agonist (GHSR-1a).

Information below is intended strictly for in-vitro experiments and in-vivo studies on animals within approved protocols.

CJC-1295 (no DAC) — synthetic GHRH 1–29 analog without Drug Affinity Complex, convenient as a short-acting probe for studying stimulation dynamics.

GHRP-2 — synthetic peptide activating GHSR-1a and associated signaling cascades, distinct from the GHRH receptor pathway.

In combination, peptides allow studying timing, pathway coordination, and downstream markers on cells/tissues/models.

Used for modeling pulsatile growth hormone release in laboratory conditions.

Used in research of metabolism, tissue regeneration, and age-related physiology on animal models.

CJC-1295 (no DAC) activates the GHRH receptor on somatotrophs, stimulating adenylate cyclase and cAMP growth, which is convenient for studying GH synthesis and secretion in models.

GHRP-2 activates GHSR-1a and PLC-dependent signaling (IP₃) with mobilization of intracellular Ca²⁺; this is useful for research of signal convergence and crosstalk.

Publications on GHRH analogs and GHSR agonists describe secretion dynamics and molecular markers in preclinical models under strictly controlled conditions.

Preclinical data demonstrate a synergistic effect with combined administration of GHRH and GHSR agonists.

Studies show an increase in the amplitude of secretory peaks without significant effect on basal secretion.

Supplied in lyophilized form for stability during storage and logistics. Identity and purity are confirmed by HPLC and MS for reproducibility of results.